Your browser doesn't support javascript.
loading
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
Maréchal, Céline; Lal, Himal; Poder, Airi; Ferguson, Murdo; Enweonye, Igwebuike; Heineman, Thomas C; Hervé, Caroline; Rheault, Paul; Talli, Jaak; Wauters, Dominique; Oostvogels, Lidia.
Afiliación
  • Maréchal C; Business and Decision Life Sciences for GSK, Wavre, Belgium. Electronic address: celine.x.marechal@gsk.com.
  • Lal H; GSK, King of Prussia, PA, USA.
  • Poder A; Clinical Research Center, Tartu, Estonia.
  • Ferguson M; Colchester Research Group, Truro, Nova Scotia, Canada.
  • Enweonye I; GSK, Amsterdam, the Netherlands.
  • Heineman TC; GSK, King of Prussia, PA, USA.
  • Hervé C; GSK, Wavre, Belgium.
  • Rheault P; Medicor Research Inc., Sudbury, Ontario, Canada.
  • Talli J; Innomedica Medical Center, Tallinn, Estonia.
  • Wauters D; GSK, Wavre, Belgium.
  • Oostvogels L; GSK, Wavre, Belgium.
Vaccine ; 37(9): 1252-1253, 2019 Feb 21.
Article en En | MEDLINE | ID: mdl-30711316

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article